4570.T
Immuno-Biological Laboratories Co.,Ltd.
グロース · 医薬品 · 医薬品 · JP
JPY 1,047.00
+1.65%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 1.0B | 969.0M | 816.0M | 794.0M |
| Cost of Revenue | 59.4M | 298.0M | 335.1M | 299.4M | 267.9M |
| Gross Profit | 152.1M | 707.0M | 634.5M | 517.3M | 526.7M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 97.7M | 425.7M | 425.1M | 413.0M | 468.3M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 97.7M | 425.7M | 425.1M | 413.0M | 468.3M |
| Cost and Expenses | 723.0M | 723.0M | 760.0M | 712.0M | 736.0M |
| Operating Income (EBIT) | 281.0M | 281.0M | 209.0M | 104.0M | 58.0M |
| Non-Operating | |||||
| Interest Income | 32.0K | 1.8M | 454.0K | 93.0K | 1.4M |
| Interest Expense | 351.0K | 1.3M | 1.3M | 1.1M | 1.1M |
| Net Interest Income | (319.0K) | 461.0K | (806.0K) | (1.0M) | 283.0K |
| Other Non-Op Income/Expense | 3.1M | 19.3M | 516.0K | 21.1M | (207.9M) |
| Non-Operating Income (excl Interest) | 6.1M | 19.0M | 4.5M | 22.2M | 17.8M |
| EBT (Pre-Tax Income) | 57.6M | 300.6M | 209.9M | 124.6M | (280.6M) |
| Income Tax Expense | (3.4M) | (28.5M) | (39.2M) | (62.0M) | 9.1M |
| Bottom Line | |||||
| Net Income | 329.0M | 329.0M | 249.0M | 186.0M | (289.0M) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 329.0M | 329.0M | 249.0M | 186.0M | (289.0M) |
| Per Share | |||||
| Basic EPS | ¥35 | ¥35 | ¥27 | ¥20 | (¥31) |
| Diluted EPS | ¥35 | ¥35 | — | — | — |
| Revenue Per Share | ¥108 | ¥108 | ¥104 | ¥88 | ¥85 |
| Shares | |||||
| Basic Shares Outstanding | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 299.5M | 224.4M | 106.3M | — |
| D&A | — | 18.5M | 15.4M | 2.3M | — |
| EBIT | 281.0M | 281.0M | 209.0M | 104.0M | 58.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026